Prostate Cancer
Reviews


Volume 8 Number 8
August 2020


Home > Disciplines > Publications > Prostate Cancer Reviews > Volume 8, Year 2020 > Number 8, August



Contents


Diagnosis, presentation


Epidemiology, risk factors, prevention


Etiology, pathogenesis, pathology


Follow-up, side effects, quality of life


Integrative medicine


Overall management


Prognosis, outcomes


Treatment



Diagnosis, presentation


Alshehri SZ, Alshahrani OS, Almsaoud NA, Al-Ghamdi MA, Alqahtani AM, Almurayyi MM, Autwdi AS, Al-Ghamdi SA, Zogan MM, Alamri AM.
The role of multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy in active surveillance for low-risk prostate cancer: A systematic review.
Ann Med Surg (Lond). 2020 Jul 17. 2020;57:171-178. doi: 10.1016/j.amsu.2020.07.015.
Review.




Arslan A, Karaarslan E, Güner AL, Sağlıcan Y, Tuna MB, Kural AR.
Comparing the Diagnostic Performance of Multiparametric Prostate MRI Versus 68Ga-PSMA PET- CT in the Evaluation Lymph Node Involvement and Extraprostatic Extension.
Acad Radiol. 2020 Aug 4. 2020;S1076-6332(20)30427-X. doi: 10.1016/j.acra.2020.07.011. Retrospective study. _




Baccaglini W, Glina FA, Pazeto CL, Medina LG, Korkes F, Bernardo WM, Sotelo R, Glina S, Marra G, Moschini M, Cathelineau X, Sanchez-Salas R.
Accuracy of MRI-guided Versus Systematic Prostate Biopsy in Patients Under Active Surveillance: A Systematic Review and Meta-analysis.
Clin Genitourin Cancer. 2020 Jul 2. 2020;S1558-7673(20)30147-6. doi: 10.1016/j.clgc.2020.06.008.
Review/Meta-analysis.




Barbosa FG, Queiroz MA, Ferraro DA, Nunes RF, Dreyer PR, Zaniboni EC, Costa LB, Bastos DA, Marin JFG, Buchpiguel CA.
Prostate-specific Membrane Antigen PET: Therapy Response Assessment in Metastatic Prostate Cancer.
Radiographics. 2020 Aug 7. 2020;40(5):1412-1430. doi: 10.1148/rg.2020200058. Review. _




Ferdinandus J, Fendler WP, Hadaschik B, Herrmann K.
Prostate-specific membrane antigen targeted PET imaging for prostate cancer recurrence.
Curr Opin Urol. 2020 Sep;30(5):635-640. doi: 10.1097/MOU.0000000000000793. Review. _




Satapathy S, Singh H, Kumar R, Mittal BR.
Diagnostic accuracy of 68Ga-PSMA PET/CT for initial detection in patients with suspected prostate cancer: A systematic review and meta-analysis.
AJR Am J Roentgenol. 2020 Jul 22. doi: 10.2214/AJR.20.23912. Review/Meta-analysis. _



Epidemiology, risk factors, prevention


Friedenreich CM, Ryder-Burbidge C, McNeil J.
Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms.
Mol Oncol. 2020 Aug 2. doi: 10.1002/1878-0261.12772.
Review.




Sargsyan A, Dubasi HB.
Milk Consumption and Prostate Cancer: A Systematic Review.
World J Mens Health. 2020 Jul 27. doi: 10.5534/wjmh.200051. Review. _



Etiology, pathogenesis, pathology


Barth DA, Juracek J, Slaby O, Pichler M, Calin GA.
lncRNA and Mechanisms of Drug Resistance in Cancers of the Genitourinary System.
Cancers (Basel). 2020 Aug 3. 2020;12(8):E2148. doi: 10.3390/cancers12082148.
Review.




Gupta M, Shorman M.
Cytomegalovirus.
StatPearls 2020 Aug 10. NCBI Bookshelf NBK459185. Review. _



Follow-up, side effects, quality of life


Bargiota A, Oeconomou A, Zachos I, Samarinas M, L Pisters L, Tzortzis V.
Adverse effects of androgen deprivation therapy in patients with prostate cancer: Focus on muscle and bone health.
J BUON. 2020 May-Jun;25(3):1286-1294. Review. _




Corona G, Filippi S, Bianchi N, Dicuio M, Rastrelli G, Concetti S, Sforza A, Maggi M.
Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer.
World J Mens Health. 2020 Aug 18. doi: 10.5534/wjmh.200109.
Review.




Cui H, Wang Y, Li F, He G, Jiang Z, Gang X, Wang G.
Quantifying observational evidence for risk of dementia following androgen deprivation therapy for prostate cancer: an updated systematic review and meta-analysis.
Prostate Cancer Prostatic Dis. 2020 Aug 19. doi: 10.1038/s41391-020-00267-3.
Review/Meta-analysis.




Lee HH, Park S, Joung JY, Kim SH.
How Does Androgen Deprivation Therapy Affect Mental Health Including Cognitive Dysfunction In Patients with Prostate Cancer?
World J Mens Health. 2020 Jul 21. doi: 10.5534/wjmh.200092.
Review.




Marcu DR, Iorga L, Diaconu CC, Spinu AD, Mischianu D, Bratu OG.
Benefits of erectile function recovery programs after radical prostatectomy (Review).
Exp Ther Med. 2020 Jun 24. 2020;20(3):2406-2410. doi: 10.3892/etm.2020.8934.
Review.



Integrative medicine


Abe SK, Inoue M.
Green tea and cancer and cardiometabolic diseases: a review of the current epidemiological evidence.
Eur J Clin Nutr. 2020 Aug 20. doi: 10.1038/s41430-020-00710-7.
Review.




Mirahmadi M, Azimi-Hashemi S, Saburi E, Kamali H, Pishbin M, Hadizadeh F.
Potential inhibitory effect of lycopene on prostate cancer.
Biomed Pharmacother. 2020 Jun 30. 2020;129:110459. doi: 10.1016/j.biopha.2020.110459.
Review.



Overall management


Broderick JM.
Experts Develop New Guideline for Advanced Prostate Cancer.
Oncology (Williston Park). 2020 Aug 12;34(8):305-306. doi: 10.46883/ONC.2020.3408.0305. Comment. _
Refers to: Lowrance W, Breau R, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans, Oh WK, Resnick M, Zietman A, Cookson MS. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline. Am Urol Assoc. 2020. http://www.auanet.org/guidelines/advanced-prostate-cancer. Guidelines. _




Lowrance W, Breau R, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans, Oh WK, Resnick M, Zietman A, Cookson MS.
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline.
Am Urol Assoc. 2020. http://www.auanet.org/guidelines/advanced-prostate-cancer. Guidelines. _




Rohan P, O'Reilly MK, Nason GJ.
Artificial Intelligence - Changing the Field of Prostate Cancer?
Ir Med J. 2020 Mar 13. 2020;113(3):45. Letter to the Editor. _




Schoots IG, Barentsz JO, Bittencourt LK, Haider MA, Macura KJ, Margolis DJA, Moore CM, Oto A, Panebianco V, Siddiqui MM, Tempany C, Turkbey B, Villeirs GM, Weinreb JC, Padhani AR.
PI-RADS Committee Position on MRI Without Contrast Medium in Biopsy Naive Men with Suspected Prostate Cancer: A Narrative Review.
AJR Am J Roentgenol. 2020 Aug 19. doi: 10.2214/AJR.20.24268. Review. _




Shore ND, Drake CG, Lin DW, Ryan CJ, Stratton KL, Dunshee C, Karsh LI, Kaul S, Kernen K, Pieczonka C, Sieber P, Stewart C, Williams M, Concepcion RS.
Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians.
Prostate. 2020 Aug 11. doi: 10.1002/pros.24053.
Guidelines.




van Leenders GJLH, van der Kwast TH, Iczkowski KA.
The 2019 International Society of Urological Pathology Consensus Conference on Prostate Cancer Grading.
Eur Urol. 2020 Aug 23. 2020;S0302-2838(20)30618-7. doi: 10.1016/j.eururo.2020.08.004. Meetings. _



Prognosis, outcomes


Saxby H, Mikropoulos C, Boussios S.
An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer.
Diagnostics (Basel). 2020 Jul 31. 2020;10(8):E549. doi: 10.3390/diagnostics10080549.
Review.




Sobhani N, Sirico M, Generali D, Zanconati F, Scaggiante B.
Circulating cell-free nucleic acids as prognostic and therapy predictive tools for metastatic castrate-resistant prostate cancer.
World J Clin Oncol. 2020 Jul 24. 2020;11(7):450-463. doi: 10.5306/wjco.v11.i7.450.
Review.




Tian S, Lei Z, Gong Z, Sun Z, Xu D, Piao M.
Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review.
Cancer Cell Int. 2020 Aug 26. 2020;20:409. doi: 10.1186/s12935-020-01508-0.
Review.



Treatment


Almeida G, Tavares JMRS.
Deep Learning in Radiation Oncology Treatment Planning for Prostate Cancer: A Systematic Review.
J Med Syst. 2020 Aug 30. 2020;44(10):179. doi: 10.1007/s10916-020-01641-3.
Review.




Antonarakis ES, Gomella LG, Petrylak DP.
When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Eur Urol Oncol. 2020 Aug 17. 2020;S2588-9311(20)30096-1. doi: 10.1016/j.euo.2020.07.005.
Review.




Crawford ED, Stanton W, Mandair D.
Darolutamide: An Evidenced-Based Review of Its Efficacy and Safety in the Treatment of Prostate Cancer.
Cancer Manag Res. 2020 Jul 13. 2020;12:5667-5676. doi: 10.2147/CMAR.S227583.
Review.




Delgadillo R, Ford JC, Abramowitz MC, Dal Pra A, Pollack A, Stoyanova R.
The role of radiomics in prostate cancer radiotherapy.
Strahlenther Onkol. 2020 Aug 21. doi: 10.1007/s00066-020-01679-9.
Review.




Enikeev D, Morozov A, Taratkin M, Barret E, Kozlov V, Singla N, Rivas JG, Podoinitsin A, Margulis V, Glybochko P.
Active Surveillance for Intermediate-Risk Prostate Cancer: Systematic Review and Meta-analysis of Current Protocols and Outcomes.
Clin Genitourin Cancer. 2020 May 22. 2020;S1558-7673(20)30116-6. doi: 10.1016/j.clgc.2020.05.008.
Review/Meta-analysis.




Kiełbik A, Szlasa W, Saczko J, Kulbacka J.
Electroporation-Based Treatments in Urology.
Cancers (Basel). 2020 Aug 7. 2020;12(8):2208. doi: 10.3390/cancers12082208.
Review.




Kim TJ, Koo KC.
Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review.
Int J Mol Sci. 2020 Jul 31. 2020;21(15):5484. doi: 10.3390/ijms21155484.
Review.




Kucharczyk MJ, So J, Gravis G, Sweeney C, Saad F, Niazi T.
A combined biological and clinical rationale for evaluating metastasis directed therapy in the management of oligometastatic prostate cancer.
Radiother Oncol. 2020 Aug 25. 2020;S0167-8140(20)30729-5. doi: 10.1016/j.radonc.2020.08.011.
Review.




Moris L, Cumberbatch MG, Van den Broeck T, Gandaglia G, Fossati N, Kelly B, Pal R, Briers E, Cornford P, De Santis M, Fanti S, Gillessen S, Grummet JP, Henry AM, Lam TBL, Lardas M, Liew M, Mason MD, Omar MI, Rouvière O, Schoots IG, Tilki D, van den Bergh RCN, van Der Kwast TH, van Der Poel HG, Willemse PM, Yuan CY, Konety B, Dorff T, Jain S, Mottet N, Wiegel T.
Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
Eur Urol. 2020 Mar 4. 2020;77(5):614-627. doi: 10.1016/j.eururo.2020.01.033. Review. _




Morozov A, Taratkin M, Barret E, Singla N, Bezrukov E, Chinenov D, Enikeev M, Gomez Rivas J, Shpikina A, Enikeev D.
A systematic review of irreversible electroporation in localised prostate cancer treatment.
Andrologia. 2020 Aug 12. 2020;e13789. doi: 10.1111/and.13789. PMID: 32786087.
Review.




Rosenberg JE, Jung JH, Edgerton Z, Lee H, Lee S, Bakker CJ, Dahm P.
Retzius-sparing versus standard robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer.
Cochrane Database Syst Rev. 2020 Aug 18. 2020;8(8):CD013641. doi: 10.1002/14651858.CD013641.pub2.
Review.




Sachdev S, Carroll P, Sandler H, Nguyen PL, Wafford E, Auffenberg G, Schaeffer E, Roach M 3rd, Evans CP, Hussain M.
Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer: A Systematic Review.
JAMA Oncol. 2020 Aug 27. doi: 10.1001/jamaoncol.2020.2832. Review. _




Sosnowski R, Kamecki H, Daneshmand S, Rudzinski JK, Bjurlin MA, Giganti F, Roobol MJ, Klotz L.
Active surveillance for low-risk prostate cancer – in pursuit of a standardized protocol.
Cent European J Urol. 2020 Jun 25. 2020;73(2):123-126. doi: 10.5173/ceju.2020.0167.
Review.




Sun M, Niaz MO, Nelson A, Skafida M, Niaz MJ.
Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer.
Cureus. 2020 Jun 30. 2020;12(6):e8921. doi: 10.7759/cureus.8921.
Review.



bottom



§§§§§§§§§§§§§§§§§§§§§§§